Previous clients:
1) New Jersey Biotech company (3 programs – two novel dry powder airway disease/delivery projects and additional antiviral project)
2) Japanese pharmaceutical company (inhaled antibiotic for US – led their pre-IND meeting)
3) California based contract research organization/clinical site (multiple programs – mostly topical drug delivery to airways)
4) California Translational Science Institute – T1 Catalyst Project – Early Translational Research [http://ctsi.ucsf.edu/etr-consultants?keys=&page=1]
5) Oligonucleotide company (neuromuscular disease)
6) San Francisco Bay Area urology device company (preparing their NDA)
7) East Coast based, large pharma (inhaled/pulmonary drug(s))
8) Global oligonucleotide company (gastrointestinal indication)
9) Small East Coast company (drug repurposing)
10) Oligonucleotide Safety Working Group – Publications coordinator [http://online.liebertpub.com/doi/pdf/10.1089/nat.2012.0383]
and recent/current clients (in 2023 and beyond):
11) Taiwan based biosimilar manufacturer – multiple programs
12) Multiple Nasal Delivery companies (based in US, Ireland, Israel, India & Switzerland)
13) San Diego dermatology focused start up
14) European inhaled formulation CDMO
15) Editor & author for a global publishing company